Ritter Pharmaceuticals | Therapeutic Treatments for Gastrointestinal Diseases

Colonic Adaptation

Ritter’s proprietary compound, RP-G28, was created to take advantage of Ritter’s gastrointestinal discovery platform based on ‘colonic adaptation’ which has the potential to spawn products for a variety of gastrointestinal diseases starting with lactose intolerance and expanding to disorders such as irritable bowel syndrome, Crohn’s disease and ulcerative colitis.

Colonic Adaptation is based on selectively colonizing microbiota in the colon by increasing the number of specific beneficial bacteria, and thus changing the colon’s microbial composition. The process has been shown to stimulate the growth of endogenous bifidobacteria and lactobacilli which after a short feeding period, become predominant in the colon resulting in reduced inflammation and improved digestion, thereby reducing digestive symptoms. Particularly for lactose intolerance both these bacterial species are lactose metabolizing, thereby minimizing or eliminating the digestive problems associated lactose intolerance.